We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Implement Diagnostics System Improves Infectious Disease Testing

By LabMedica International staff writers
Posted on 17 Dec 2019
A team of scientists recently began using machine-learning tools and assessed them in a prospective clinical trial to determine whether artificial intelligence could perform better than specialists in clinical test interpretation.

The tool automates and standardizes quantitative polymerase chain reaction (PCR) test analysis, enabling real-time monitoring on a test-by-test basis. More...
The company developed the machine-learning system in part to address shortages of trained laboratory staff, as well as to help laboratories improve internal efficiencies, both in terms of time and money saved.

Scientists from Glasgow Royal Infirmary (Glasgow, UK) undertook a prospective clinical study to evaluate the accuracy and impact when automating the manual data-analysis and quality control steps associated with routine clinical pathogen testing using real-time PCR (qPCR). They evaluated the use of the tool when used as a final interpretation and verification step for routine in-house qPCR tests for respiratory pathogens and for norovirus for a total of 22,200 interpretations. The tests were run over the course of a month. The tool is called PCR.ai and is produced by Diagnostics.ai (London, UK).

The team reported that there was 100% concurrence between validated respiratory virus and norovirus detection by their manual routine analysis method and PCR.Ai. Furthermore, there were significant routine savings with PCR.ai of 45 min/respiratory run and 32 min/norovirus run. They concluded that PCR.ai is a highly accurate time-saving tool that reduces complexity of qPCR analysis and hence the need for specialists and hands-on time. It demonstrated capabilities to enable the scientists to get results out more quickly with lower costs and less risk of errors.

Typically, the company works with a lab's existing data, which is fed to the learning machine during a training phase. Any inconsistencies are flagged and dealt with during an interactive phase. Once completed, PCR.ai is handed off to users to run in real-time on a standalone server that is not accessible to the firm. Revenues are derived via a service and support model, influenced by volumes and support needs. The firm's emphasis, however, is on reducing costs within laboratories.

Aron Cohen, BA, CEO of Diagnostics.ai, said, “The model, especially in the UK, tends to be savings driven. I think that's an important approach we have taken, that in addition to improving quality and accuracy, turnaround time, and getting better results faster, reducing costs is a vital piece of that puzzle. Some places have six- or seven-day weeks including night shifts. We need to be able to provide support for that. It's important to have the resources to be able to cope. I think taking in over 20,000 results, and proving we could do it faster, with no errors, and even picking up mistakes made in the manual process are really impressive results for any clinical or AI product.” The study was published in the November, 2019 issue of the Journal of Clinical Virology.

Related Links:
Glasgow Royal Infirmary
Diagnostics.ai


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Clinical Chemistry System
P780
New
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Ultrasensitive NeXT Personal Test detects the earliest molecular signs of recurrence in breast cancer patients (Photo courtesy of Personalis)

Ultrasensitive Test Could Identify Earliest Molecular Signs of Metastatic Relapse in Breast Cancer Patients

HR+ (hormone receptor-positive) HER2- (human epidermal growth factor receptor 2-negative) breast cancer represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.